Thalidomide and Dacarbazine for Metastatic Melanoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2004 by National Center for Research Resources (NCRR).
Recruitment status was Active, not recruiting
Information provided by:
National Center for Research Resources (NCRR)
First received: September 9, 2000
Last updated: June 23, 2005
Last verified: January 2004
The purpose of this clinical trial is to assess the activity of thalidomide in combination with dacarbazine (DTIC) in patients with metastatic melanoma. Safety and toxicity of the two drugs will also be assessed. Dacarbazine is the standard medical treatment for metastatic melanoma. It has been shown to produce tumor shrinkage in approximately 20% of patients with advanced melanoma. This shrinkage is usually incomplete and lasts a short time. Thalidomide is a drug that inhibits tumor blood vessel growth. It can be given orally. It is hoped that this combination can be given to patients with metastatic melanoma without causing too much toxicity while increasing the response rate.
||Primary Purpose: Treatment
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Patients with metastatic melanoma.
- Lesions must be measurable.
- Patient must have the following minimum labs: ANC> 1500/mm3, Hemoglobin > 8 mg/dl; platelets > 100,000 mm3; and liver function tests < 5x normal; and creatinine < 1.5 mg/dl.
- ECOG performance status > 2.
- No prior therapy with DTIC or thalidomide
- No other history of malignancy other than curatively resected basal cell carcinoma of the skin or carcinoma in situ of the cervix.
- Patients must not be pregnant or lactating.
- Sexually active men and women of childbearing age must use adequate contraception. All patients must understand the potential for severe birth defects with thalidomide and must be able to follow instructions to avoid conception while taking thalidomide
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006200
|Kaplan Comprehensive Cancer Center
|New York, New York, United States, 10016 |
No publications provided
History of Changes
|Other Study ID Numbers:
|Study First Received:
||September 9, 2000
||June 23, 2005
||United States: Federal Government
Additional relevant MeSH terms:
ClinicalTrials.gov processed this record on May 21, 2015
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Nevi and Melanomas
Angiogenesis Modulating Agents
Physiological Effects of Drugs